These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28492461)

  • 21. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
    D'Onofrio G; O'Connor PG; Pantalon MV; Chawarski MC; Busch SH; Owens PH; Bernstein SL; Fiellin DA
    JAMA; 2015 Apr; 313(16):1636-44. PubMed ID: 25919527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.
    Roux P; Rojas Castro D; Ndiaye K; Briand Madrid L; Laporte V; Mora M; Maradan G; Morel S; Spire B; Carrieri P
    Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):46. PubMed ID: 29096661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma.
    Bhatraju EP; Ludwig-Barron N; Takagi-Stewart J; Sandhu HK; Klein JW; Tsui JI
    Drug Alcohol Depend; 2020 Oct; 215():108253. PubMed ID: 32890919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.
    Deyo-Svendsen M; Cabrera Svendsen M; Walker J; Hodges A; Oldfather R; Mansukhani MP
    J Prim Care Community Health; 2020; 11():2150132720931720. PubMed ID: 32507023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
    Woodcock EA; Lundahl LH; Greenwald MK
    Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of buprenorphine in the management of heroin addiction.
    Sung S; Conry JM
    Ann Pharmacother; 2006 Mar; 40(3):501-5. PubMed ID: 16434562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Buprenorphine to Treat Opioid Use Disorder.
    Bartholow LAM; Pope J
    J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stigma associated with medication treatment for young adults with opioid use disorder: a case series.
    Hadland SE; Park TW; Bagley SM
    Addict Sci Clin Pract; 2018 May; 13(1):15. PubMed ID: 29730987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
    McKeganey N; Russell C; Cockayne L
    J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine in the treatment of heroin addiction: déjà vu all over again.
    Stimmel B
    J Addict Dis; 2012; 31(1):1-2. PubMed ID: 22356663
    [No Abstract]   [Full Text] [Related]  

  • 32. Detoxification with buprenorphine of a pregnant heroin addict.
    Annitto WJ
    Am J Addict; 2000; 9(1):92-3. PubMed ID: 10914298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users.
    Gandhi DH; Jaffe JH; McNary S; Kavanagh GJ; Hayes M; Currens M
    Addiction; 2003 Apr; 98(4):453-62. PubMed ID: 12653815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
    Collins ED; Kleber HD; Whittington RA; Heitler NE
    JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
    Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized clinical trial.
    Stein M; Herman D; Conti M; Anderson B; Bailey G
    Addiction; 2020 Jan; 115(1):82-94. PubMed ID: 31430414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engagement, retention, and abstinence for three types of opioid users in Florida.
    McCabe BE; Santisteban DA; Mena MP; Duchene DM; McLean C; Monroe M
    Subst Use Misuse; 2013 Jun; 48(8):623-34. PubMed ID: 23750774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2000; (3):CD002025. PubMed ID: 10908521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intent to Refer: Exploring Bias Toward Specific Medication-Assisted Treatments by Community Corrections Employees.
    Streisel SE
    Subst Use Misuse; 2018 Dec; 53(14):2421-2430. PubMed ID: 29958042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.